scholarly journals Telomerase Transcriptional Targeting of Inducible Bax/TRAIL Gene Therapy Improves Gemcitabine Treatment of Pancreatic Cancer

2008 ◽  
Vol 16 (2) ◽  
pp. 252-260 ◽  
Author(s):  
Séverine Wack ◽  
Soukaina Rejiba ◽  
Céline Parmentier ◽  
Marc Aprahamian ◽  
Amor Hajri
Keyword(s):  
Pancreatic Cancer ◽  
Gene Therapy ◽  
Transcriptional Targeting ◽  
Gemcitabine Treatment

Somatostatin Receptor Subtype 2 Gene Therapy Inhibits Pancreatic Cancer in Vitro

2002 ◽  
Vol 105 (1) ◽  
pp. 58-64 ◽  
Author(s):  
William E. Fisher ◽  
YuanQing Wu ◽  
Felipe Amaya ◽  
David H. Berger
Keyword(s):  
Pancreatic Cancer ◽  
Gene Therapy ◽  
Somatostatin Receptor ◽  
Receptor Subtype ◽  
Somatostatin Receptor Subtype 2

CaSm/gemcitabine chemo-gene therapy leads to prolonged survival in a murine model of pancreatic cancer

Surgery ◽  
2001 ◽  
Vol 130 (2) ◽  
pp. 280-288 ◽  
Author(s):  
Joseph R. Kelley ◽  
Melissa M. Fraser ◽  
Clifford W. Schweinfest ◽  
John N. Vournakis ◽  
Dennis K. Watson ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Gene Therapy ◽  
Murine Model ◽  
Prolonged Survival

scholarly journals Comparative evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy

2007 ◽  
Vol 6 (5) ◽  
pp. 679-685 ◽  
Author(s):  
Ilya V. Ulasov ◽  
Angel A. Rivera ◽  
Adam M. Sonabend ◽  
Adam M. Sonabend ◽  
Ming Wang ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Comparative Evaluation ◽  
Transcriptional Targeting

Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition

2019 ◽  
Vol 207 ◽  
pp. 56-69 ◽  
Author(s):  
Maher Y. Abdalla ◽  
Iman M. Ahmad ◽  
Satyanarayana Rachagani ◽  
Kasturi Banerjee ◽  
Christopher M. Thompson ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Cells ◽  
Heme Oxygenase ◽  
Heme Oxygenase 1 ◽  
Pancreatic Cancer Cells ◽  
Gemcitabine Treatment

Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer

2020 ◽  
pp. 106002802096935
Author(s):  
Shigeru Ishida ◽  
Yoko Makihara ◽  
Hiroyuki Watanabe ◽  
Takafumi Nakashima ◽  
Kenichiro Nagata ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer ◽  
Predictive Factors ◽  
Preventive Measures ◽  
Regression Analyses ◽  
Multivariable Analyses ◽  
Vascular Pain ◽  
Pain Symptoms ◽  
Gemcitabine Treatment ◽  
Hot Pack

Background: Peripheral intravenous injection of gemcitabine often causes vascular pain; however, preventive measures have not yet been established. Objectives: This study focused on identifying predictive factors for gemcitabine-induced vascular pain. Methods: We retrospectively analyzed risk factors for developing vascular pain in patients with pancreatic cancer receiving gemcitabine infusions at our institution. Infusions were divided into groups according to presence or absence of vascular pain symptoms, and variables were compared. Odds ratios for risk factors were calculated using logistic regression analyses. Results: Overall, 272 patients with pancreatic cancer were subjected to 725 gemcitabine infusions, and of these, 18.4% (n = 50) experienced vascular pain. There were significant differences in the gemcitabine dose ( P = 0.025), dose of gemcitabine/body surface area (BSA; P = 0.004), concentration of gemcitabine ( P = 0.025), and hot pack use ( P = 0.011) between the vascular pain and no vascular pain groups. Multivariable analyses indicated that gemcitabine dose/BSA and lack of hot pack use were risk factors for developing vascular pain. Moreover, on administration of a higher dosage (>930 mg/m2), the incidence of vascular pain in patients using a hot pack (6.7%) was significantly lower than that in patients not provided a hot pack (16.2%). Conclusions and Relevance: High gemcitabine dosages and lack of hot pack use were predictive factors for gemcitabine-induced vascular pain in patients with pancreatic cancer. Patients receiving gemcitabine treatment should apply a hot pack to the injection site. Scrupulous clinical attention is required for patients presenting with these risk factors to improve pain management.

Effective Gene Therapy for Pancreatic Cancer by Cytokines Mediated by Restricted Replication-Competent Adenovirus

2000 ◽  
Vol 11 (2) ◽  
pp. 223-235 ◽  
Author(s):  
Fuyuhiko Motoi ◽  
Makoto Sunamura ◽  
Lianghao Ding ◽  
Dan Gabriel Duda ◽  
Yoko Yoshida ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Gene Therapy

scholarly journals Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Carlotta Spano ◽  
Giulia Grisendi ◽  
Giulia Golinelli ◽  
Filippo Rossignoli ◽  
Malvina Prapa ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Gene Therapy ◽  
Soluble Trail

Bax-Induction Gene Therapy of Pancreatic Cancer

2002 ◽  
Vol 106 (2) ◽  
pp. 346-351 ◽  
Author(s):  
Elissa C. Pirocanac ◽  
Rounak Nassirpour ◽  
Meng Yang ◽  
Jinwei Wang ◽  
Stephanie R. Nardin ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Gene Therapy
Sign in / Sign up

Export Citation Format

Share Document